HUTCHMED (China) Limited (HCM)
NEUTRALFundamental
42
Kurs
$12.28
Marktkapitalisierung
$2.12B
Teil 1 · Was das Unternehmen wert ist
Übersicht
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilanz & Liquidität
Umsatz
$109M
Letzte 12 Monate bis zum zuletzt gemeldeten Quartal — Schätzung aus Kennzahlen je Aktie
Nettogewinn
$91M
Letzte 12 Monate bis zum zuletzt gemeldeten Quartal — Schätzung aus Kennzahlen je Aktie
Freier Cashflow
$-19M
Gesamtes Eigenkapital
$1.26B
Gesamtverbindlichkeiten
$95M
Current Ratio
5.64
Zinsdeckungsgrad
-
Schulden/EBITDA
-
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$8.56
Aktueller Kurs
$12.28
Sicherheitsmarge
-43.4%
Innerer-Wert-Spanne
$5.56 - $11.56
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
23.26
ROE
1.5%
P/B-Verhältnis
8.58
P/FCF
-
Bruttomarge
38.7%
ROIC
0.1%
Rentabilitäts-Radar
Value Creation (Economic Moat)
ROIC
0.1%
WACC
10.4%
ROIC − WACC
-10.3 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamentalanalyse-Kriterien
Bestanden (8)
- Gross Margin 38.7%
- Debt/Equity ratio
- Current Ratio
- ROE 37.0%
- Revenue Growth 5Y 19.2%
- Analyst Consensus 85% Buy
- Earnings Surprise avg 95.6%
- Net Margin Trend 83.3% vs 6.0%
Nicht bestanden (9)
- Price CAGR -0.72%
- ROIC 0.1%
- P/B Ratio 8.58
- Operating Margin -7.1%
- Positive Free Cash Flow
- Price below Graham Number
- DCF valuation (Unknown)
- Earnings Quality (OCF/NI) 0.04
- Piotroski F-Score 1/9
Nicht verfügbar (10)
- EPS data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- PEG Ratio (need PE > 0 and growth > 0)
- Share Dilution (missing shares data)
Piotroski F-Score
Ernsthafte finanzielle Bedenken
Gewinnqualität
Niedrige Qualität: Rechnungslegung prüfen
Aktienverwässerung
Aktienrückkäufe. Aktionärsfreundlich
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. Chig Fung Cheng BEc, CA | Acting CEO, CFO & Executive Director | 58 |
| Dr. Wei-Guo Su B.Sc., Ph.D. | CEO, Chief Scientific Officer & Executive Director (Leave of Absence) | 66 |
| Ms. Yiling Cui | Executive VP & Head of Operations | - |
| Dr. Xinhui Hu Ph.D. | Executive Vice President & Chief Technical Officer | 52 |
| Mr. David Ng | Head of Investor Relations & Capital Strategies | - |
| Mr. Charles George Rupert Nixon | Group General Counsel | 55 |
| Mr. Kin Hung Lee M.B.A. | Senior Vice President of Corporate Management & Communications | 48 |
| Ms. Selina Zhang | Senior Vice President of Global Human Resources | - |
| Dr. Qingmei Wang Ph.D. | Executive Vice President of Business Development & Strategic Alliances | 62 |
| Dr. Thomas Fu | Senior Vice President of Global Quality | - |
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Latest News
Recent headlines for HCM, sourced from Markets Gazette.